Triazole Derivatives as PDE4 Activators
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies lack small molecule activators for long forms of cyclic nucleotide phosphodiesterase-4 (PDE4) enzymes, which are essential for reducing excessive intracellular cAMP signaling associated with various disorders, due to the absence of effective small molecule activators.
Innovation Solution
Development of triazole derivative compounds of Formula I and Formula II, which selectively activate long forms of PDE4 enzymes, thereby reducing intracellular cAMP levels and providing therapeutic benefits for disorders mediated by excessive cAMP signaling.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If small molecule activators are developed for PDE4 long forms, then therapeutic effectiveness for cAMP-mediated disorders is improved, but prior to this invention, no such activators existed leaving a therapeutic gap
Solution Approach 1:
The patent applies parameter changes by developing small molecule compounds with specific chemical structures (Formulas I and II) that have the appropriate molecular parameters to activate PDE4 long forms. The compounds feature specific substituent patterns (R1-R11 groups) that can be optimized to achieve the desired activation effect, transforming the therapeutic landscape from no activators available to having multiple candidate compounds with tunable properties.
2Measurement precision
If triazole derivative compounds are designed to selectively activate long forms of PDE4, then selectivity for long forms over short forms is improved, but the complexity of achieving isoform-specific activation increases
Solution Approach 1:
The patent applies local quality by designing compounds where specific local features (substituent groups at particular positions on the triazole core) determine isoform selectivity. The R1-R11 substituents create local chemical environments that preferentially interact with long form PDE4 isoforms, allowing selective activation through localized molecular features rather than requiring complete structural redesign.
Solution Approach 2:
The patent applies segmentation by dividing the molecule into a core triazole structure and variable substituent groups (R1-R11). This modular approach allows independent optimization of the core scaffold for PDE4 binding while tuning the substituents for isoform selectivity, reducing overall design complexity through functional decomposition.
3Reliability
If compounds are developed to reduce intracellular cAMP levels, then therapeutic benefit for excessive cAMP signaling is improved, but the risk of affecting other cellular processes dependent on cAMP increases
Solution Approach 1:
The patent applies the intermediary principle by using small molecule compounds as mediators that specifically activate PDE4 long forms to reduce cAMP levels. These compounds act as controlled intermediaries between the therapeutic goal (cAMP reduction) and the enzyme system, providing regulated activation that can be tuned to achieve therapeutic benefits while minimizing uncontrolled off-target effects on other cAMP-dependent processes.
Data Source
AI summary
Compounds of Formula (I), which are activators of long form cyclic nucleotide phosphodiesterase-4 (PDE4) enzymes, are provided. Methods and uses of these compounds for the treatment or prevention of disorders requiring a reduction of second messenger responses mediated by cyclic 3′,5′-adenosine monophosphate (cAMP) are also described.